Maze Therapeutics (NASDAQ:MAZE) CMO Sells $445,680.62 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 16,142 shares of the stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $27.61, for a total value of $445,680.62. Following the sale, the chief marketing officer directly owned 16,142 shares of the company’s stock, valued at approximately $445,680.62. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harold Bernstein also recently made the following trade(s):

• On Wednesday, July 1st, Harold Bernstein sold 14,609 shares of Maze Therapeutics stock. The shares were sold at an average price of $29.90, for a total transaction of $436,809.10.

Maze Therapeutics Price Performance

Maze Therapeutics stock opened at $27.18 on Monday. The stock has a market capitalization of $1.51 billion, a PE ratio of -10.79 and a beta of 2.22. Maze Therapeutics, Inc. has a twelve month low of $12.81 and a twelve month high of $53.65. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09. The company has a 50 day moving average of $27.79 and a 200-day moving average of $32.95.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, hitting analysts’ consensus estimates of ($0.76). On average, equities research analysts anticipate that Maze Therapeutics, Inc. will post -2.71 EPS for the current fiscal year.

Hedge Funds Weigh In On Maze Therapeutics

A number of large investors have recently modified their holdings of MAZE. Royal Bank of Canada grew its holdings in shares of Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after acquiring an additional 363 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in Maze Therapeutics during the fourth quarter valued at approximately $39,000. Caitong International Asset Management Co. Ltd bought a new position in Maze Therapeutics in the fourth quarter valued at approximately $43,000. California State Teachers Retirement System grew its stake in Maze Therapeutics by 138.0% in the fourth quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock valued at $55,000 after purchasing an additional 766 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Maze Therapeutics during the 2nd quarter worth approximately $48,000.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on MAZE. Wall Street Zen cut Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. BTIG Research restated a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a research note on Wednesday, August 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $66.00.

Key Stories Impacting Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: BTIG issued a Buy rating. The endorsement adds to the constructive analyst view of Maze’s pipeline and could support investor confidence. Maze Therapeutics Earns Buy Rating from BTIG Research
• Positive Sentiment: Maze strengthened its board with two experienced executives. Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., bring extensive clinical, pharmaceutical, partnering, and commercialization expertise. Management also highlighted additional MZE829 data in late 2026 or early 2027, initial MZE782 data in 2027, and additional trial starts next year. Maze Therapeutics Announces Appointments to Its Board of Directors
• Positive Sentiment: HC Wainwright raised all of its reported EPS forecasts. Estimates improved for third-quarter 2026, fourth-quarter 2026, and fiscal years 2026 through 2030. For example, FY2026 EPS was revised to a loss of $2.81 from $2.96, while FY2030 was revised to a loss of $0.72 from $0.74, indicating expectations for a somewhat faster reduction in losses over time.
• Neutral Sentiment: Maze reported second-quarter 2026 financial results and recent business highlights. The available report headline does not provide the detailed financial figures, so the earnings release’s impact cannot be fully assessed from the supplied information. Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
• Negative Sentiment: Maze remains unprofitable. HC Wainwright’s revised forecasts still call for substantial losses through 2030, and its FY2026 estimate of a $2.81 loss is slightly worse than the $2.73 consensus forecast.
• Negative Sentiment: Reported insider activity is a concern. Company insiders have recorded sales but no purchases during the past six months, potentially weighing on sentiment.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.